top of page

VOLBELLA™ XC

I N J E C T A B L E S

Placeholder

iStock-1180270376.jpg

VOLBELLA™ XC is an injectable filler based on hyaluronic acid (HA) that provides improvement in lip contours while boosting volume, smoothing vertical creases (smoker’s lines), and achieving symmetry.

VOLBELLA™ XC lip injections are recommended for smoother, softer consistency that mimics the natural feel of your lips for a longer time. Feel lip fullness with VOLBELLA™ XC.

WHAT CAN VOLBELLA™ XC LIP INJECTIONS CAN DO FOR YOU?
​​

  • Diminish vertical lip lines filler (aka smoker’s lines)

  • Accentuate the border of your lips

  • Plump up your lips to make them fuller

  • Enhance the cupid’s bow (the “M” part of your mid-upper lip)

 

 

VOLBELLA™ XC with lidocaine is a new dermal filler treatment for the lips and perioral area. Designed not only for gentle restoration of natural looking lip volume, it can also be used for defining lip contours, treating oral commissures, smoothing fine lines around the lips and supporting the ‘marionette’ lines down the chin.​​

HOW DO VOLBELLA™ XC LIP INJECTIONS WORK?


Developed using Allergan’s proprietary Vycross technology, VOLBELLA™ XC with lidocaine filler is formulated with an innovative combination of low and high molecular weight technology, which improves the cross-linking efficiency of HA chains. This more effective cross-linking allows for a lower concentration of HA to be used, which results in less swelling. The Vycross technology delivers an ultra-smooth gel, which results in a natural look and feel, as well as improved duration.

 

This unique technology allows the product to absorb less water, resulting in considerably reduced swelling compared to more traditional fillers. Not only is there less downtime, the treatment itself is made as pain free as possible by the built-in lidocaine anesthetic. Results can last up to twelve months with full correction.

WHAT ARE THE TYPICAL AREAS THAT ARE TREATED?


VOLBELLA™ XC treats lost lip volume, defines lip contours, treats the corners of the mouth (that turn down making you look like sad), smooths smoker’s lines and helps erase marionette lines (the lines that go from the corners of your mouth down to your chin).

CAN VOLBELLA™ XC TREATMENTS BE COMBINED WITH OTHER TREATMENTS?


Vertical lines (smoker’s lines) are difficult to treat but VOLBELLA™ XC treatments can be combined with laser procedures that stimulate collagen and Botox which helps relax the muscles around the mouth. Combo treatments improve the overall final rejuvenation of the mouth area and increase the longevity of the improvements.

  • JUVÉDERM® is the #1 chosen collection of hyaluronic acid fillers in the US*. Each product in the JUVÉDERM® Collection of Fillers adds volume to a different area of the face—without surgery. All JUVÉDERM® fillers are smooth, crystal-clear gels that are administered by injection in your aesthetic healthcare provider's office.

    *December 2022 Provider Survey Data (n=938)

  • Different formulations are approved to either volumize cheeks, smooth smile lines, smooth lines around the mouth, plump the lips, define the chin, improve the jawline, or improve the appearance of undereye hollows. The results are long-lasting, and can be customized by your licensed specialist to help you achieve your aesthetic goals.

    The JUVÉDERM® Collection of Fillers are for adults over 21.

    JUVÉDERM® VOLLURE® XC softens moderate to severe facial wrinkles and folds (eg, nasolabial folds) by adding volume around the nose and mouth.

    JUVÉDERM® VOLUMA® XC is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile.

    JUVÉDERM® VOLBELLA® XC adds volume to the lips for a subtle plump, softens the appearance of perioral lines, and improves the appearance of undereye hollows.

    JUVÉDERM® ULTRA PLUS XC smooths moderate to severe facial wrinkles and folds around your nose and mouth.

    JUVÉDERM® ULTRA XC adds fullness and plumps lips as well as smooths and corrects moderate to severe wrinkles and folds in adults.

    JUVÉDERM® VOLUX® XC adds volume along the jawline area to improve jawline definition in patients with moderate to severe loss. The added volume augments the shape and structure of the lower face.

  • Products in the JUVÉDERM® Collection are FDA approved and have been widely studied. Numerous clinical studies have been completed globally evaluating the safety and effectiveness of Vycross® technology fillers. Please see below for Important Safety Information.

  • Vycross® is the #1 chosen filler technology in the world. Vycross® is a proprietary technology designed by Allergan Aesthetics for use in its JUVÉDERM® Collection of hyaluronic acid (HA) fillers, including JUVÉDERM® VOLUMA® XC, JUVÉDERM® VOLLURE® XC, JUVÉDERM® VOLBELLA® XC, and JUVÉDERM® VOLUX® XC. Vycross® technology cross-links HA molecules to create a smooth and efficiently cross-linked filler. All Vycross® fillers contain a small quantity of lidocaine to decrease injection-site pain.

    *December 2022 Provider Survey Data (n=938)

  • The JUVÉDERM® Collection of Fillers is made from hyaluronic acid (HA). HA is a natural substance in the skin that delivers nutrients, helps the skin retain moisture and softness. Each product in the JUVÉDERM® Collection of Fillers is made from a modified form of HA.

  • Your aesthetic healthcare provider will take your medical history and provide a facial analysis. Be prepared to discuss your aesthetic areas of concern. This is not a surgical treatment. Actual treatment with JUVÉDERM® injectable gels can take 15 minutes to 60 minutes, depending on which areas of your face is being treated.

  • JUVÉDERM® injectable gels labeled with "XC" contain pain-reducing lidocaine to help manage pain or discomfort during the injection. You may also ask your aesthetic healthcare provider about a topical numbing cream or ice to help further minimize discomfort.

  • The cost not only includes the price of the product but, more importantly, the skill and expertise of the specialist or healthcare professional who is administering your treatment. Look for someone who is licensed and trained and has experience treating patients with the JUVÉDERM® Collection. Be wary of discount products or “cheap” JUVÉDERM® Collection treatments — if it sounds too good to be true, it probably is.

    It is more important to find an experienced specialist who will take the time to understand your treatment goals and develop a treatment plan that is right for you.

  • Join Allē, the new and improved loyalty program by the makers of JUVÉDERM®, for savings on treatments within the JUVÉDERM® Collection. With Allē, you can earn 200 points for qualifying JUVÉDERM® treatments that you can redeem for savings on future treatments.

    Allē also rewards you for getting a variety of in-office treatments from other brands, too. Then, redeem points for savings on your favorite Allergan Aesthetics brands. Use points as you go, or store them in your Wallet for big savings later. 100 Points = $10 toward qualifying products and treatments.

  • You will see results immediately/instantly.

  • Results may last one year to two years, with optimal treatment and depending on the formula used and the area treated. Please read each product description to see how long results last with each formula and treatment area, based on what was observed in clinical studies.

  • Do not receive JUVÉDERM® injectable gel fillers if you have a history of severe allergic reactions (anaphylaxis), or if you are allergic to lidocaine or the proteins (Gram-positive bacterial proteins) used to make hyaluronic acid (HA) in JUVÉDERM® injectable gel fillers.

  • JUVÉDERM® fillers have established safety profiles. The safety and effectiveness of JUVÉDERM® fillers have been evaluated in numerous clinical studies worldwide.

  • Treatment with JUVÉDERM® fillers is not permanent. Depending on the JUVÉDERM® filler used and the treatment area, results may last one year to two years with optimal treatment.

  • The most common side effects are redness, swelling, pain, and tenderness. Minimize exercise, sun or heat exposure, and alcoholic beverages within the first 24 hours following treatment to avoid worsening these side effects. Talk to your licensed specialist about post-care instructions following treatment and please see below for more Important Safety Information.

IMPORTANT SAFETY INFORMATION

Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

APPROVED USES

JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21.

JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.

JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 21.

JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.

JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.

JUVÉDERM® Injectable Gel Fillers Important Information

ARE THERE ANY REASONS WHY I SHOULD NOT RECEIVE ANY JUVÉDERM® FORMULATION?

Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

 

WHAT WARNINGS SHOULD MY DOCTOR ADVISE ME ABOUT?

  • One of the risks with using dermal fillers is the unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. Most of these events are irreversible.

  • If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should notify your health care practitioner immediately.

  • The use of dermal fillers where skin sores, pimples, rashes, hives, cysts, or infections are present should be postponed, as this may delay healing or make skin problems worse

  • The effectiveness of removal of any dermal filler has not been studied.

 

WHAT PRECAUTIONS SHOULD MY DOCTOR ADVISE ME ABOUT?

  • JUVÉDERM® VOLBELLA® XC should only be injected into undereye hollows by doctors who have completed the necessary training for this treatment area. To find a doctor, visit Juvederm.com/find-a-specialist. Doctors who complete the training will be listed with a symbol

  • The safety of these products for use during pregnancy or while breastfeeding has not been studied

  • The safety of JUVÉDERM® VOLUMA® XC has not been studied in patients under 35 years or over 65 years for cheek augmentation, or under 22 years and over 80 years for chin augmentation. The safety of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC has not been studied in patients under 22 years, and the safety of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC has not been studied in patients under 18 years

  • The safety and effectiveness of treatment with JUVÉDERM® products in anatomical regions outside of their approved uses have not been established in clinical studies

  • If you have a history of excessive scarring (thick, hard scars) or pigmentation disorders, treatment in these patients has not been studied and may result in additional scars or changes in pigmentation

  • If you are planning other procedures including laser treatments or a chemical peel, there is a possible risk of inflammation at the treatment site if these procedures are performed closely before or after JUVÉDERM® injectable gel treatment

  • Tell your doctor if you are on therapy used to reduce your body's natural defense system (such as steroids, chemotherapy, and medicines to treat autoimmune diseases, HIV, and AIDs), as these may increase your risk of infection; and medications that can prolong bleeding (such as aspirin, ibuprofen, or other blood thinners), as these may result in increased bruising or bleeding at the injection site.

  • Avoid applying makeup for 12 hours after treatment and minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment, as these may cause temporary redness, swelling, and/or itching at the injection site

  • JUVÉDERM® VOLUMA® XC was not studied in patients with significant loose skin of the chin, neck, or jaw

  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied

  • Patients who experience skin injury near the site of JUVÉDERM® VOLUMA® XC injection may be at a higher risk for adverse events

  • Tell your doctor if you have already been injected with dermal fillers in the same area as the one(s) you are about to be treated for. This information helps your doctor decide when and whether you should get treatment

WHAT ARE POSSIBLE SIDE EFFECTS OF TREATMENT?

The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.

These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).

As with all skin injection procedures, there is a risk of infection.


To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1-877-345-5372. Please also visit Juvederm.com or talk to your doctor for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

JUVÉDERM® Collection of Fillers Important Information

INDICATIONS

JUVÉDERM® VOLUMA® XC is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.

JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.

JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM® Ultra XC injectable gel is indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.


WARNINGS

  • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur

  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

PRECAUTIONS

  • To minimize the risk of potential complications, these products should only be used by healthcare professionals with appropriate experience and training on facial anatomy and product use in indicated area(s), vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications

  • The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications

  • The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each have not been established in controlled clinical studies

  • The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied

  • The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age in cheek augmentation and for patients between 22 and 80 years of age for chin augmentation

  • The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established

  • As with all transcutaneous procedures, dermal filler implantation carries a risk of infection

  • Dermal fillers should be used with caution in patients on immunosuppressive therapy

  • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites

  • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events

  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site

  • The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established

  • The safety of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI

  • JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study

  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied

  • Patients may experience late-onset adverse events with the use of dermal fillers, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC

  • Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs) body mass per year. The safety of injecting greater amounts has not been established

  • Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied

ADVERSE EVENTS

The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA® XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC , or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA® XC, most resolved within 30 days.


To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support Department at 1-877-345-5372. Please visit JuvedermDFU.com for more information.


Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-voluma-xc_dfu.pdf for JUVÉDERM® VOLUMA® XC


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volux-xc_dfu.pdf for JUVÉDERM® VOLUX® XC


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-vollure-xc_dfu.pdf for JUVÉDERM® VOLLURE® XC


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volbella_dfu.pdf for JUVÉDERM® VOLBELLA® XC


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-plus- xc_dfu.pdf for JUVÉDERM® ULTRA PLUS XC


Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-xc_dfu.pdf for JUVÉDERM® ULTRA XC

SKINVIVE™ by JUVÉDERM® Important Information

 

INDICATIONS

SKINVIVE™ by JUVÉDERM® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21.

 

IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product.


WARNINGS

  • Do not inject into blood vessels. Introduction of this product into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur

  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

  • Injection site responses consist mainly of short-term inflammatory symptoms and generally resolve within 1 week. Refer to the ADVERSE EVENTS

PRECAUTIONS

  • To minimize the risk of potential complications, this product should only be used by healthcare professionals who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection

  • Discuss all potential risks of soft tissue injections with patients prior to treatment and ensure patients are aware of signs and symptoms of potential complications

  • Limit patients to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs.) body mass per year. The safety of injecting greater amounts has not been established

  • This product is intended for improving skin smoothness and fine lines of the cheeks. The safety and effectiveness of use in other areas of the body have not been established

  • Injection of more than 6.0 mL of this product (initial and touch-up treatment combined) for improvement of skin smoothness and fine lines of the cheeks has not been studied

  • As with all transcutaneous procedures, injections of the product carry a risk of infection

  • The safety for use during pregnancy, in breastfeeding females, and in patients under 22 years has not been established

  • The safety in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied

  • This product should be used with caution in patients on immunosuppressive therapy

  • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites

  • Patients may experience late onset AEs with use of injectable gel implants, including this product

  • This product should only be used by healthcare professionals who have appropriate experience and who are knowledgeable about the anatomy and the product for use in the face

  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site

 

ADVERSE EVENTS

In clinical studies, injection site responses (ISRs) observed in >5% of treated subjects included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most ISRs were mild. Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess.


To report an adverse reaction with SKINVIVE™ by JUVÉDERM®, please call Allergan® Product Support Department at 1-877-345-5372. Please visit SKINVIVEDFU.com for more information.


SKINVIVE™ by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.

IMPORTANT SAFETY INFORMATION JUVÉDERM® 

Placeholder

Placeholder

 

Placeholder

  • Placeholder text!

  • Placeholder text!

  • Placeholder text!

Schedule online anytime by engaging with the SKNCRAFT chat box located at the bottom right corner, simply type "schedule appointment" to get started or feel free to call or text 281-256-1003 

READY TO

SCHEDULE?

Yale Street BW.jpg

Add a Title

Add paragraph text. Click “Edit Text” to customize this theme across your site. You can update and reuse text themes.

bottom of page